BAX (Baxter International Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by BAX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Andrew P. Hider | President and CEO | F | — | — |
| 2026-09-03 | James Teaff | President, CCS | F | — | — |
| 2026-09-03 | Julie Foster | President, Front Line Care | F | — | — |
| 2026-06-03 | James Teaff | President, CCS | F | — | — |
| 2026-06-03 | Steven P. Wallace | President, Adv. Surgery | F | — | — |
| 2026-06-03 | Anita A Zielinski | SVP, Interim CFO, CAO & Cntrlr | A | — | — |
| 2026-05-07 | William A. Ampofo II | Director | A | — | — |
| 2026-05-07 | Jeffrey A Craig | Director | A | — | — |
| 2026-05-07 | Michael R. McDonnell | Director | A | — | — |
| 2026-05-07 | David Brent Shafer | Director | A | — | — |
| 2026-05-07 | PATRICIA MORRISON | Director | A | — | — |
| 2026-05-07 | NANCY M SCHLICHTING | Director | A | — | — |
| 2026-05-07 | Amy McBride Wendell | Director | A | — | — |
| 2026-05-07 | David S. Wilkes | Director | A | — | — |
| 2026-03-10 | Joel T. Grade | EVP and CFO | F | — | — |
| 2026-03-10 | Reazur Rasul | EVP,Group Pres,Healthcare | F | — | — |
| 2026-03-10 | David S. Rosenbloom | EVP and General Counsel | F | — | — |
| 2026-03-10 | Maria Cecilia Soriano | Group Pres., ITT & Pharma. | F | — | — |
| 2026-03-10 | Anita A Zielinski | SVP, CAO and Controller | F | — | — |
| 2026-03-03 | Anita A Zielinski | SVP, CAO and Controller | A | — | — |
| 2026-03-03 | Joel T. Grade | EVP and CFO | A | — | — |
| 2026-03-03 | David S. Rosenbloom | EVP and General Counsel | MIXED | — | — |
| 2026-03-03 | Maria Cecilia Soriano | Group Pres., ITT & Pharma. | MIXED | — | — |
| 2026-03-03 | Reazur Rasul | EVP,Group Pres,Healthcare | F | — | — |
| 2026-03-03 | Cynthia Carlisle | Executive Vice President, CHRO | A | — | — |
| 2026-03-03 | Andrew P. Hider | President and CEO | A | — | — |
| 2026-02-18 | Michael R. McDonnell | Director | A | — | — |
| 2026-02-11 | Joel T. Grade | EVP and CFO | MIXED | — | — |
| 2026-02-11 | Reazur Rasul | EVP,Group Pres,Healthcare | MIXED | — | — |
| 2026-02-11 | David S. Rosenbloom | EVP and General Counsel | MIXED | — | — |
| 2026-02-11 | Maria Cecilia Soriano | Group Pres., ITT & Pharma. | MIXED | — | — |
| 2025-12-16 | Jeanne K Mason | EVP, Chief HR Officer | F | — | — |
| 2025-12-03 | Joel T. Grade | EVP and CFO | F | — | — |
| 2025-09-04 | James W Borzi | EVP,Chief Supply Chain Officer | F | — | — |
| 2025-09-04 | Joel T. Grade | EVP and CFO | A | — | — |
| 2025-09-04 | Andrew P. Hider | President and CEO | A | — | — |
| 2025-09-04 | Alok Sonig | EVP,Group President,Pharma | F | — | — |
| 2025-08-21 | David Brent Shafer | Director | F | — | — |
| 2025-06-04 | David S. Rosenbloom | EVP and General Counsel | F | — | — |
| 2025-05-08 | Jeffrey A Craig | Director | A | — | — |
| 2025-05-08 | William A. Ampofo II | Director | A | — | — |
| 2025-05-08 | PATRICIA MORRISON | Director | A | — | — |
| 2025-05-08 | Stephen N. Oesterle | Director | A | — | — |
| 2025-05-08 | STEPHEN H RUSCKOWSKI | Director | A | — | — |
| 2025-05-08 | NANCY M SCHLICHTING | Director | A | — | — |
| 2025-05-08 | Cathy R Smith | Director | A | — | — |
| 2025-05-08 | Amy McBride Wendell | Director | A | — | — |
| 2025-05-08 | David S. Wilkes | Director | A | — | — |
| 2025-03-10 | James W Borzi | EVP,Chief Supply Chain Officer | MIXED | — | — |
| 2025-03-10 | Joel T. Grade | EVP and CFO | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 36,001,790 | — |
| — | Director | 23,008,124 | — |
| — | Chairman of the Board and CEO | 689,991 | — |
| — | Chairman, CEO, President | 568,565 | — |
| — | President and CEO | 518,447 | — |
| — | EVP and CFO | 271,674 | — |
| — | EVP, Chief HR Officer | 199,853 | — |
| — | EVP, Chief Financial Officer | 177,899 | — |
| — | EVP, Chief Operating Officer | 177,362 | — |
| — | Corporate Vice President | 163,092 | — |
| — | EVP and General Counsel | 138,216 | — |
| — | EVP,Group President,Pharma | 128,219 | — |
| — | Corporate Vice President | 125,899 | — |
| — | EVP,Group Pres,Healthcare | 125,557 | — |
| — | Corporate Vice President | 109,990 | — |
| — | EVP, Group Pres, Kidney Care | 105,186 | — |
| — | SVP, President, EMEA | 102,145 | — |
| — | CVP and General Counsel | 102,087 | — |
| — | Corporate Vice President | 86,868 | — |
| — | Corporate Vice President | 83,031 | — |
| — | Corporate Vice President | 81,665 | — |
| — | EVP, Chief Operating Officer | 76,495 | — |
| — | Group Pres., ITT & Pharma. | 75,045 | — |
| — | Interim CEO and Chair | 72,804 | — |
| — | EVP,Chief Supply Chain Officer | 71,948 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BAX quote page; the site-wide leaderboard is on the insider transactions hub.